Purchase this article with an account.
Francis Char DeCroos, David Carleton Reed, Murtaza K Adam, David A Salz, Omesh Gupta, Allen C Ho, Carl D Regillo; Prospective, Multicenter Investigation of Aflibercept Treat and Extend Therapy for Neovascular Age-related Macular Degeneration (ATLAS Study): One and Two Year Results. Invest. Ophthalmol. Vis. Sci. 2016;57(12):No Pagination Specified.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the visual outcomes, anatomic outcomes, and the number of injections required when using a treat and extend regimen with aflibercept for neovascular age-related macular degeneration (NVAMD).
Forty eyes of forty participants met inclusion criteria for this multicenter, prospective, open label study. These eyes were treated every 4 weeks until no signs of macular exudation by clinical assessment including spectral domain optical coherence tomography. The treatment intervals were then extended by 2 weeks until either an exudative recurrence or a treatment interval of 16 weeks was achieved. Main outcome measures included change from baseline visual acuity, change in central retinal thickness (CRT), mean number of annual injections, treatment interval, and adverse events. Wilcoxon signed rank test was used for analysis.
Forty eyes of forty patients were enrolled. An average of 8.0 treatments resulted in a median best corrected visual acuity (BCVA) improvement of 11 letters (p < 0.001) and CRT decrease of 163 micrometers (p < 0.001) during the first year. An average of 5.9 treatments resulted in a sustained median BCVA improvement of 11 letters (p < 0.001) and CRT decrease of 161 micrometers (p < 0.001) during the second year. A treatment interval of eight weeks or longer was obtained in 71% and 82% of patients at one and two years respectively. A treatment interval of twelve weeks or longer was obtained in 35% and 41% of patients at one and two years respectively. No ocular or related systemic adverse events were observed.
Aflibercept treat and extend therapy for NVAMD led to visual and anatomic improvement at year 1, and these gains were sustained at year 2 with a decreased treatment burden relative to year 1. A sustained treatment interval of twelve weeks or longer was achieved in more than a third of patients.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only